Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
- 15 May 2010
- journal article
- research article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 105 (10), 1413-1419
- https://doi.org/10.1016/j.amjcard.2010.01.003
Abstract
No abstract availableKeywords
Funding Information
- Ionis Pharmaceuticals
This publication has 31 references indexed in Scilit:
- Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemiaJournal of Lipid Research, 2010
- Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic MiceCirculation, 2008
- Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemiaNature Clinical Practice Cardiovascular Medicine, 2008
- Niacin and Lipoprotein(a): Facts, Uncertainties, and Clinical ConsiderationsThe American Journal of Cardiology, 2008
- New targets and emerging therapies for reducing LDL cholesterolCurrent Opinion in Lipidology, 2007
- Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group RecommendationsThe American Journal of Cardiology, 2005
- Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatinAmerican Heart Journal, 2004
- Approaches for the sequence-specific knockdown of mRNANature Biotechnology, 2003
- A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemiaAtherosclerosis, 2003
- N‐acetylcysteine and serum concentrations of lipoprotein(a)Journal of Internal Medicine, 1991